Vertex, Inc. is rated a Buy due to steady growth, margin expansion, recurring revenue, and high retention. Learn more about ...

A screen of companies benefiting from AI include Samsung Electronics (KR:005930), SK Hynix (KR:000660), Airbus (FR:AIR), Nokia (NOK), Visa (V), Mastercard (MA), Coca-Cola (KO) and CVS Health (CVS), ...

Eli Lilly LLY announced that it entered a definitive agreement to acquire the privately held clinical-stage biotech Orna Therapeutics in a deal valued at $2.4 billion. This transaction includes both ...

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with ...

Q4 2025 earnings call highlights: 2026 revenue outlook, ALYFTREK progress, CASGEVY/JOURNAVX growth, and renal pipeline—read now.

Vertex Pharmaceuticals forecast 2026 revenue largely in line with analysts estimates on Thursday, as the drugmaker bets on growth for its cystic fibrosis treatments as well as contributions from newer ...

Vertex Pharmaceuticals Inc. VRTX shares are trending on Thursday night. Shares of the Massachusetts-based biotechnology company fell 1.24% in after-hours trading to $459.25 on Thursday despite ...

Vertex (NASDAQ:VERX) executives used the company’s fourth-quarter earnings call to outline a plan to reaccelerate growth ...

KING OF PRUSSIA, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results ...

Vertex Pharmaceuticals VRTX reported adjusted earnings of $5.03 per share for the fourth quarter of 2025, missing the Zacks ...